Connect with us

News

VarmX appoints Dr. Gerard Short as Chief Medical Officer

gbafNews28

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).

As CMO, Dr. Short will be responsible for overseeing the clinical development of VarmXs pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies.

Dr. Short brings to VarmX extensive clinical development expertise, with a particular focus on rare diseases and gene therapy for haematological disorders. With more than 20 years of experience working within the sector “ for both big pharma and biotech “ he has established a strong track record of successfully leading teams in clinical development and medical affairs.

Alexander Vos, CEO of VarmX, said: We are delighted to welcome a person of Gerards calibre to our team. His proven knowledge in clinical, medical, and regulatory affairs, combined with his history of successfully advancing programs into the clinic, will be instrumental as VarmX enters a key transition phase to becoming a clinical stage company in 2021.

Im pleased to be joining VarmX at this stage in the Companys evolution, commented Dr. Gerard Short, CMO of VarmX, on his appointment. I recognise the potential that the lead compound, VMX-C001, holds as an effective and differentiated antidote to oral anticoagulants, reversing the severe consequences that patients face. As such, I look forward eagerly to further progress the program towards the start of clinical studies later this year.

Dr. Short joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science. During this time, he grew the medical, clinical, and regulatory groups, and established an in-house pharmacovigilance function. Further, he advanced gene therapy clinical programmes in haemophilia B and Fabrys disease. Before Freeline, Dr. Short spent a decade at Genzyme, preceding and following its acquisition by Sanofi. He held roles of increasing responsibility, ultimately serving as Global Development Team Leader leading innovative treatment programmes targeting Pompes disease (phase 3) and acute leukaemia. Prior to Genzyme, Dr. Short established his clinical development career through a series of roles at Novartis, Pfizer and Sanofi-Synthelabo following eight years as a clinical practitioner.

Dr. Short received his Bachelor of Medicine (MBBS) degree from St. Marys Hospital Medical School (now part of Imperial College) and holds a Master of Business Administration (MBA) degree from London Business School. In addition, he is a Member of the Royal College of Physicians (MRCP UK) and a Fellow of the Faculty of Pharmaceutical Medicine (FFPM).

ENDS

Notes to Editors

About VarmX

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmXs lead compound VMX-C001 is a modified recombinant blood factor X based on the venom of the Australian brown snake, Pseudonaja textilis. The compound is being developed for the treatment of severe spontaneous bleeding in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Ysios Capital, INKEF Capital, Lundbeckfonden Ventures, LSP, BioGeneration Ventures and the regional economic development fund, InnovationQuarter. For more information: www.varmx.com.

VarmX B.V.

Alexander Vos, CEO

Tel: +31 6 46 736 915

Instinctif Partners (media enquiries)

Melanie Toyne-Sewell / Nathan Billis

Tel: +44 20 7457 2020

Leon Melens (Dutch press)

Tel: +31 6 538 16 427

E-mail: [email protected]

News

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cooper Tire & Rubber Company – CTB

gbafNews28

NEW YORK, Feb. 27, 2021 /PRNewswire/ —

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Cooper Tire & Rubber Company (“CTB” or the “Company”) (CTB) relating to its proposed merger with The Goodyear Tire & Rubber Company. Under the terms of the agreement, CTB shareholders will receive 0.907 shares of Goodyear common stock and $41.75 in cash per share.

The investigation focuses on whether Cooper Tire & Rubber Company and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Click here for more information: http://monteverdelaw.com/case/cooper-tire-rubber-company. It is free and there is no cost or obligation to you.

Monteverde & Associates PC Logo

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in Cooper Tire & Rubber Company and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde–associates-pc-announces-an-investigation-of-cooper-tire–rubber-company–ctb-301236802.html

SOURCE Monteverde & Associates PC

Continue Reading

News

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. – PRAH

gbafNews28

NEW YORK, Feb. 27, 2021 /PRNewswire/ —

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating PRA Health Sciences, Inc. (“PRAH” or the “Company”) (PRAH) relating to its proposed acquisition by ICON plc. Under the terms of the agreement, PRAH shareholders will receive 0.4125 shares of ICON stock and $80.00 in cash per share.

The investigation focuses on whether PRA Health Sciences, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Click here for more information: http://monteverdelaw.com/case/pra-health-sciences-inc. It is free and there is no cost or obligation to you.

Monteverde & Associates PC Logo

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in PRA Health Sciences, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde–associates-pc-announces-an-investigation-of-pra-health-sciences-inc–prah-301236801.html

SOURCE Monteverde & Associates PC

Continue Reading

News

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Longevity Acquisition Corp. – LOAC

gbafNews28

NEW YORK, Feb. 26, 2021 /PRNewswire/ —

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Longevity Acquisition Corp. (“LOAC” or the “Company”) (LOAC) relating to its proposed merger with 4D Pharma PLC. Under the terms of the agreement, LOAC shareholders will receive 7.5315 shares of 4D Pharma per share.

The investigation focuses on whether Longevity Acquisition Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Click here for more information: http://monteverdelaw.com/case/longevity-acquisition-corp. It is free and there is no cost or obligation to you.

Monteverde & Associates PC Logo

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in Longevity Acquisition Corp. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde–associates-pc-announces-an-investigation-of-longevity-acquisition-corp–loac-301236799.html

SOURCE Monteverde & Associates PC

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News29 mins ago

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Longevity Acquisition Corp. – LOAC

NEW YORK, Feb. 26, 2021 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national...

gbafNews28 gbafNews28
News29 mins ago

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. – PRAH

NEW YORK, Feb. 27, 2021 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national...

gbafNews28 gbafNews28
News29 mins ago

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cooper Tire & Rubber Company – CTB

NEW YORK, Feb. 27, 2021 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national...

gbafNews28 gbafNews28
News31 mins ago

Unique French-English bilingual programme at the Canadian International School (CIS) expanding from August 2021

SINGAPORE – Media OutReach – 22 February 2021 – The Canadian International School (CIS) in Singapore is delighted to announce...

gbafNews28 gbafNews28
News31 mins ago

HKGSEO Provides Free Website SEO Analysis and Consulting Services

HONG KONG SAR – Media OutReach – 22 February 2021 – The COVID-19 epidemic has lasted for nearly a year....

gbafNews28 gbafNews28
News31 mins ago

Media OutReach Expands into China with Strategic Partnership with Xinhua Finance Agency

The newswire continues growing its foothold in Asia by opening its 7th office in the region   HONG KONG SAR...

gbafNews28 gbafNews28
News31 mins ago

Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

HONG KONG SAR – Media OutReach – 22 February 2021 – This announcement is made by Ocumension Therapeutics (the “Company“,...

gbafNews28 gbafNews28
News31 mins ago

Citi Plus® Official Launch Ceremony

HONG KONG SAR – Media OutReach – 22 February 2021 Photo 1 Mr Lawrence Lam, Consumer Business Manager of Citibank...

gbafNews28 gbafNews28
News31 mins ago

Hong Kong Productivity Council and Hong Kong Computer Society Sign Pact to Enhance the Adoption of Emerging Technologies in Hong Kong

HONG KONG SAR – Media OutReach – 22 February 2021 – The Hong Kong Productivity Council (HKPC) and the Hong...

gbafNews28 gbafNews28
News31 mins ago

Citibank Officially Launches Citi Plus®

Co-creating With Target Clients to Suit Their Banking and Investment Needs Fostering Financial Education to Level-Up Digital Natives Through Mobile...